اعلان هااااااااااااااام


Translate

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments (Sarepta Therapeutics Inc)

Thursday, March 7, 2013

WN.com - Health News
Latest headlines from WN Network
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments (Sarepta Therapeutics Inc)
Mar 7th 2013, 13:14

(Source: Sarepta Therapeutics Inc) Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments Upcoming Meetings With FDA Will Determine Fastest Path to Pursue Eteplirsen Approval; Additional Drugs for Duchenne Muscular Dystrophy (DMD) Continue to Progress Through Preclinical Development; 2013 Financial Guidance of $18-24 Million in Revenues; $85-115 Million in Operating Loss; Cash Balance of $187 Million at Year-End 2012 CAMBRIDGE, MA -- (MARKETWIRE) -- 03/07/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three months and full year ended...
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2012 Financial Results and Recent Corporate Developments (Sarepta Therapeutics Inc)

Post a Comment